NEVIMINE SUSPENSION (Each 5ml contains Nevirapire Hemihydrate 50mg

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations.

Adults: Refer to the BNF for specific dosing recommendations.

Mechanism of action

The exact mechanism of action for Hemi is not explicitly detailed in the available resources, but compounds with similar structure may act by modulating neurotransmitter levels, inhibiting enzymes, or affecting cellular signaling pathways.

Pharmacodynamics

Hemi may exhibit pharmacodynamic properties that include modulation of neural activity or inhibition of specific biochemical pathways. Its effects could be dose-dependent and vary based on the therapeutic context.

Pharmacokinetics

The pharmacokinetic profile of Hemi, including absorption, distribution, metabolism, and excretion, is not well-documented in the provided resources. Generally, compounds in this class may undergo first-pass metabolism and have a variable half-life.

Dosage

Children: Refer to the specific formulation or active ingredient for dosing information.

Adults: Refer to the specific formulation or active ingredient for dosing information.

Mechanism of action

The mechanism of action of hemihydrate forms of drugs can vary widely depending on the specific compound. In many cases, the hemihydrate form enhances the solubility of the active ingredient, which facilitates its dissolution and absorption in the gastrointestinal tract.

Pharmacodynamics

Pharmacodynamics of hemihydrate compounds generally relates to the pharmacological effects that arise from the active drug once it is absorbed. The effects may vary based on the specific drug and its therapeutic target, but overall, the hemihydrate form aims to improve efficacy by ensuring adequate plasma concentrations are achieved more effectively than non-hydrated forms.

Pharmacokinetics

The pharmacokinetics of hemihydrate drugs typically demonstrate improved dissolution rates due to the presence of water, which can lead to increased absorption. This may result in quicker onset of action and modified half-lives. The specifics of absorption, distribution, metabolism, and excretion will depend on the active ingredient and its properties.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether this drug is excreted in human milk. Caution should be exercised when administered to a nursing mother.

Storage

Store at room temperature, away from moisture and heat. Keep container tightly closed.

Indications

• HIV-1 infection
• HIV-1 infection in combination therapy

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Nevirapine binds to the reverse transcriptase enzyme of HIV-1, inhibiting its activity. This prevents the transcription of viral RNA into DNA, thereby blocking the replication of the virus. Its action is non-competitive and does not require phosphorylation to become active, distinguishing it from nucleoside reverse transcriptase inhibitors (NRTIs).

Pharmacodynamics

Nevirapine exhibits dose-dependent pharmacological effects with a significant impact on reducing viral load in HIV-infected individuals. It is effective against HIV-1 but has less activity against HIV-2. The drug's efficacy can be influenced by the presence of specific mutations in the reverse transcriptase gene, which can confer resistance to the drug.

Pharmacokinetics

Nevirapine is well absorbed orally, with peak plasma concentrations occurring approximately 4 hours after dosing. It is extensively metabolized in the liver, primarily by cytochrome P450 enzymes, particularly CYP3A4. The elimination half-life ranges from 25 to 30 hours, allowing for once-daily or twice-daily dosing schedules. Nevirapine is excreted mainly in urine as metabolites, with less than 1% of the dose recovered unchanged.

Contra-indications

• Hypersensitivity to nevirapine or any component of the formulation
• Severe hepatic impairment
• Concurrent use with certain medications that are strong inducers of CYP3A4

Adverse effects

• Rash, which can progress to severe skin reactions
• Hepatotoxicity, including elevated liver enzymes
• Nausea and vomiting
• Fatigue
• Headache
• Dizziness

Interactions

• May interact with other drugs metabolized by CYP3A4
• Can reduce plasma concentrations of methadone
• May increase the risk of toxicity with drugs that are hepatically metabolized

Precautions

• Caution in patients with a history of liver disease
• Monitor liver function tests regularly during treatment
• Consider potential drug interactions carefully before initiation

Pregnancy

Nevirapine is classified as category B. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Nevirapine is excreted in breast milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets
• Oral suspension